KRT6B and bladder transitional cell carcinoma: In summary, our study indicated that KRT6B was involved in the progression of BLCA through EMT and the immune response, which implied that KRT6B in BLCA-derived exosomes could be a prognostic marker for BLCA and a new candidate target for BLCA therapy.